Trial Profile

A Phase 1b Multiple Ascending Dose (MAD) Study of EC5026 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EC 5026 (Primary)
Indications Pain
Focus Adverse reactions; Pharmacokinetics
Sponsors EicOsis

Most Recent Events

08 Jan 2025 Status changed from recruiting to completed.
30 Jan 2024 According to an EicOsis Human Health, the initial results from cohort 1 appear to replicate very favorable safety profile we observed in Phase 1a clinical studies where there were no adverse behavioral, cardiovascular, or neurological effects over five ascending single-dose levels and the maximum dose level that was 5 to 10-fold higher than the anticipated analgesic dose in humans.
30 Jan 2024 According to an EicOsis Human Health, today announced the initiation of Phase 1b multiple-ascending dose clinical trial to test the safety of EC5026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com